tus insignias Rango 52S $146–$303 92% of range Calificación del Analista BUY 23 analysts Precio Objetivo $305 +5% upside P/E -60.5 ROE -7.7% Margen de Beneficio Neto -6.0%

CRL Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

03
Precio $290.19
Capitalización Bursátil (MRQ) $13.85B
P/E (TTM) -60.5
BPA (TTM) $-4.80
Ingresos (TTM) $4.00B
ROE (TTM) -7.7%
Deuda/Capital (MRQ) 0.0
Rango 52S $146–$303

CRL Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

04
rango
barras

La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.

Acerca de Charles River Laboratories International, Inc. Common Stock Descripción general de la empresa de Wikipedia

05 · wikidata

Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.

Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.

As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.

History

Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.

In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.

The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.

Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.

In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.

In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.

In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.

Acquisitions

In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.

Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.

In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.

In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.

From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.

The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.

In July 2015, the company announced it would acquire Celsis International for $212 million.

In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.

In August 2017, the business announced it would acquire Brains On-Line.

In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.

In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.

In August 2020, the company announced it would acquire Cellero for $38 million in cash.

In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.

In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.

In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.

In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.

In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.

In April 2022, the company announced it would acquire Explora BioLabs.

In January 2023, the business announced it would acquire SAMDI Tech, Inc.

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

sectorHealthcare industriaLife Sciences Tools & Services empleados18 300 paísUS

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

06
Ingresos$4.02B
2016-12-31 → 2025-12-27
BPA$-2.91
2016-12-31 → 2025-12-27
Flujo de caja libre$518M
2016-12-31 → 2025-12-27
Margen neto-6.0%
2016-12-31 → 2025-12-27
Valoración y ratios 07–12

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica Tendencia a 5 años CRL promedio 5A Mediana de Pares Veredicto
P/E (TTM) -60.5promedio 5A ≈191.6 ≈191.6 · ·
P/S (TTM) 3.5promedio 5A ≈3.2 ≈3.2 4.9 Infravalorado
P/C (MRQ) 4.9promedio 5A ≈4.1 ≈4.1 3.6 Valor razonable
EV / EBITDA 32.8promedio 5A ≈16.9 ≈16.9 25.4 Infravalorado
Precio / FCF (TTM) 37.4promedio 5A ≈28.8 ≈28.8 · ·
Precio / Flujo de Caja (TTM) 23.8promedio 5A ≈17.3 ≈17.3 26.2 Infravalorado
EV / Revenue (EV / Ingresos) 3.5promedio 5A ≈3.1 ≈3.1 · ·
EV / FCF 27.1promedio 5A ≈28.3 ≈28.3 · ·
Precio / Valor Contable Tangible (MRQ) 5.4 · · ·

La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.

valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

14
Sorpresa Media 8.9%
Próximo informe Nov 03, 2026
PeríodoInformeEPS ActualEPS est.Sorpresa
30 de junio de 2026 Ago 12, 2026 $3.02 $2.76 9.2%
31 de marzo de 2026 $2.06 $1.96 5.0%
31 de diciembre de 2025 $2.39 $2.37 0.98%
30 de septiembre de 2025 $2.43 $2.36 2.9%
30 de junio de 2025 $3.12 $2.52 23.7%
31 de marzo de 2025 $2.34 $2.10 11.4%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

15
Estado de resultados 15
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue $4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B$1.36B$1.30B
Cost of Revenue ········$290M$277M$264M$266M
SG&A Expense $743M$751M$748M$665M$620M$529M$518M$444M$371M$365M$300M$269M
Operating Income $25M$227M$617M$651M$590M$433M$351M$331M$288M$238M$206M$178M
Interest Expense ··$137M$59M$74M$86M$61M$64M$30M$28M$15M$12M
Interest Income $5M$9M$5M$780.0K$652.0K$834.0K$2M$812.0K$690.0K$1M$1M$1M
Other Non-op $-23M$-17M$96M$31M$-36M$100M$12M$13M$38M$12M$3M$11M
Pretax Income $-100M$93M$581M$623M$481M$447M$304M$282M$297M$223M$195M$178M
Income Tax $43M$68M$101M$130M$82M$82M$50M$54M$171M$67M$43M$48M
Net Income $-144M$22M$475M$486M$391M$364M$252M$226M$123M$155M$149M$127M
EPS (Basic) $-2.91$0.20$9.27$9.57$7.77$7.35$5.17$4.72$2.60$3.29$3.21$2.72
EPS (Diluted) $-2.91$0.20$9.22$9.48$7.60$7.20$5.07$4.62$2.54$3.23$3.13$2.66
Shares (Basic) 49,564,00051,380,00051,227,00050,812,00050,293,00049,550,00048,730,00047,947,00047,481,00047,014,00046,496,00046,627,000
Shares (Diluted) 49,564,00051,628,00051,451,00051,301,00051,425,00050,611,00049,693,00049,018,00048,564,00047,958,00047,634,00047,558,000
EBITDA $428M$589M$931M$955M$855M$668M$549M$493M$419M$364M$301M$274M
Balance general 30
Métrica Tendencia 202520242023202220212020201920182017201620152014
Cash & Equivalents $214M$195M$277M$234M$241M$228M$238M$195M$164M$118M$118M$160M
Short-term Investments ····$1M$1M$941.0K$885.0K$28M$4M$21M·
Receivables $709M$721M$780M$752M$643M$618M$514M$472M$430M$364M$270M$258M
Inventory $299M$279M$380M$256M$199M$186M$161M$128M$115M$96M$94M$89M
Prepaid Expense $129M$106M$83M$108M$97M$73M$56M$49M$81M$45M$47M$45M
Other Current Assets ·····$0$300.0K$300.0K$0$45M$47M$73M
Current Assets $1.45B$1.40B$1.61B$1.44B$1.27B$1.20B$1.02B$898M$827M$657M$559M$579M
PP&E (Net) $1.66B$1.60B$1.64B$1.47B$1.29B$1.12B$1.04B$933M$782M$756M$678M$677M
PP&E (Gross) $3.19B$3.06B$2.98B$2.63B$2.39B$2.21B$2.02B$1.81B$1.58B$1.46B$1.32B$1.33B
Accum. Depreciation $1.54B$1.45B$1.34B$1.16B$1.10B$1.09B$978M$874M$801M$706M$645M$655M
Goodwill $2.76B$2.85B$3.10B$2.85B$2.71B$1.81B$1.54B$1.25B$805M$788M$439M$321M
Intangibles $340M$723M$864M$955M$1.06B$788M$689M$611M$370M$394M$281M$281M
Other Non-current Assets $293M$278M$309M$148M$152M$353M$213M$144M$124M$88M$72M$73M
Total Assets $7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B$2.07B$1.87B
Accounts Payable $149M$140M$169M$206M$198M$122M$111M$66M$78M$68M$37M$34M
Accrued Liabilities $270M$232M$228M$220M$229M$150M$139M$107M$90M$84M$89M$67M
Current Liabilities $1.12B$994M$1.06B$1.09B$1.03B$840M$710M$558M$464M$430M$312M$295M
Capital Leases $434M$484M$419M$390M$253M$156M$116M·····
Deferred Tax $95M$107M$191M$216M$240M$217M$167M$144M$90M$56M$48M$23M
Other Non-current Liabilities $138M$195M$223M$175M$243M$205M$183M$179M$195M$159M$89M$100M
Total Liabilities $3.92B$4.02B$4.54B$4.58B$4.43B$3.35B$3.03B$2.52B$1.87B$1.86B$1.30B$1.17B
Long-term Debt ·······$1.61B$1.09B$1.18B$814M$717M
Total Debt $166.0K$155.0K$3M$1M$101.0K$47M$36M$1.65B$1.12B$1.21B$836M$754M
Common Stock $492.0K$511.0K$513.0K$509.0K$505.0K$498.0K$489.0K$482.0K$875.0K$863.0K$855.0K$845.0K
Retained Earnings $1.39B$1.81B$1.89B$1.43B$981M$625M$280M$42M$289M$165M$11M$-139M
Treasury Stock $0$0$0$0$0$0$0$55.0K$1.66B$1.55B$1.54B$1.42B
AOCI $-172M$-317M$-196M$-262M$-165M$-139M$-178M$-173M$-145M$-254M$-136M$-74M
Stockholders' Equity $3.16B$3.46B$3.60B$2.98B$2.53B$2.11B$1.63B$1.32B$1.05B$837M$733M$672M
Liabilities + Equity $7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B$2.07B$1.87B
Shares Outstanding 49,217,00051,141,00051,338,00050,944,00050,480,00049,767,00048,936,00048,209,00047,402,00047,363,00046,698,00047,327,000
Flujo de Efectivo 18
Métrica Tendencia 202520242023202220212020201920182017201620152014
D&A $403M$362M$314M$304M$266M$235M$198M$162M$131M$127M$95M$96M
Stock-based Comp $71M$70M$72M$74M$71M$56M$57M$47M$44M$44M$40M$31M
Deferred Tax $-75M$-67M$-51M$-33M$-20M$2M$-21M$-10M$28M$3M$4M$9M
Amort. of Intangibles $179M$138M$137M$147M$125M$112M$90M$65M$41M$42M$24M$26M
Restructuring $100M$107M$30M$8M$7M$13M$14M$10M$5M$18M$8M$8M
Other Non-cash $483M$348M$-126M$-211M$53M$-111M$-5M$16M$-8M$-28M$-395.0K·
Operating Cash Flow $738M$735M$684M$620M$761M$547M$481M$441M$318M$317M$307M$252M
CapEx $219M$233M$319M$325M$229M$167M$141M$140M$82M$55M$63M$57M
Investing Cash Flow $-209M$-245M$-563M$-608M$-1.44B$-602M$-682M$-955M$-73M$-693M··
Debt Issued $1.23B$1.08B$776M$2.95B$6.95B$2.23B$3.36B$2.76B$237M$1.04B··
Net Debt Issued $1.23B$1.08B$776M$2.95B$6.95B$2.23B$3.36B$2.76B····
Stock Repurchased $361M$119M$24M$39M$41M$24M$18M$14M$107M$12M$117M$122M
Net Stock Activity $-361M$-119M$-24M$-39M$-41M$-24M$-18M$-14M$-107M$-12M$-117M$-122M
Financing Cash Flow $-537M$-551M$-86M$-42M$673M$47M$232M$558M$-208M$381M··
Net Change in Cash $10M$-79M$43M$-5M$13M$-7M$43M$31M$46M$-69.0K$-43M$4M
Taxes Paid $120M$126M$90M$76M$75M$60M$54M$68M····
Free Cash Flow $518M$502M$365M$295M$532M$380M$340M$301M$236M$245M$225M$195M
Levered FCF ··$252M$248M$471M$309M$290M$250M$223M$226M$213M$186M
Rentabilidad 7
Métrica Tendencia 202520242023202220212020201920182017201620152014
Operating Margin 0.63%5.6%14.9%16.4%16.7%14.8%13.4%14.6%15.5%14.1%15.1%13.7%
Net Margin -3.6%0.55%11.5%12.2%11.0%12.5%9.6%10.0%6.6%9.2%10.9%·
Pretax Margin -2.5%2.3%14.1%15.7%13.6%15.3%11.6%12.4%16.0%13.3%14.3%13.7%
EBITDA Margin 10.7%14.5%22.6%24.0%24.2%22.8%20.9%21.8%22.5%21.6%22.1%21.1%
ROA -2.0%0.28%6.0%6.7%6.2%7.1%5.9%6.7%4.4%6.5%7.6%·
ROE -4.4%0.63%14.4%17.6%16.8%19.4%17.1%19.2%13.1%19.7%21.2%·
ROIC 1.1%1.8%14.2%17.3%19.3%16.4%17.6%9.0%5.6%8.1%10.2%9.1%
Liquidez y Solvencia 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Current Ratio 1.31.41.51.31.21.41.41.61.81.51.82.0
Quick Ratio 0.80.91.00.90.91.01.11.21.31.11.21.4
Debt / Equity 0.00.00.00.00.00.00.01.31.11.41.11.1
LT Debt / Equity ·······1.21.01.41.11.1
Interest Coverage ··4.511.08.05.05.85.29.78.613.714.9
Eficiencia 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Asset Turnover 0.50.50.50.50.60.60.60.70.70.70.70.7
Inventory Turnover ········2.72.92.93.0
Receivables Turnover 5.65.45.45.75.65.25.35.04.75.35.25.4
Por Acción 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Book Value / Share $64.30$67.69$70.06$58.42$50.21$42.49$33.40$27.33$22.05$17.67$15.70$14.20
Revenue / Share $81.01$78.45$80.26$77.50$68.84$57.77$52.75$46.23$38.25$35.06··
Cash Flow / Share $14.88$14.23$13.29$12.08$14.79$10.80$9.68$9.00$6.55$6.26··
Cash / Share $4.34$3.81$5.39$4.59$4.78$4.59$4.86$4.05$3.46$2.48$2.53$3.38
EPS (TTM) $-2.91$0.20$9.22$9.48$7.60$7.20$5.07$4.62$2.54$3.23$3.13$2.66
Tasas de Crecimiento 7
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue YoY -0.85%-1.9%3.9%12.3%21.1%·······
Revenue CAGR 3Y 0.33%4.6%12.2%·········
Revenue CAGR 5Y 6.6%···········
EPS YoY ·-97.8%-2.7%24.7%5.6%·······
EPS CAGR 3Y ·-70.3%8.6%·········
Net Income YoY ·-95.3%-2.4%24.4%7.3%·······
Net Income CAGR 3Y ·-61.6%9.2%·········
Valoración (TTM) 14
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue TTM $4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B$1.36B$1.30B
Net Income TTM $-144M$22M$475M$486M$391M$364M$252M$226M$123M$155M$149M$127M
Market Cap $10.02B$9.52B$12.14B$11.10B$18.64B$12.53B$7.43B$5.39B$5.19B$3.61B$3.74B$3.04B
Enterprise Value $9.81B$9.33B$11.86B$10.87B$18.40B$12.34B$7.23B$6.84B$6.12B$4.70B$4.46B$3.64B
P/E -70.0930.825.623.048.635.030.024.243.123.625.624.2
P/S 2.52.42.92.85.34.32.82.42.82.12.72.3
P/B 3.22.83.43.77.45.94.54.15.04.35.14.5
P / Tangible Book 166.0···········
P / Cash Flow 13.613.017.717.924.522.915.512.216.312.013.012.1
P / FCF 19.319.033.237.635.033.021.817.922.014.716.615.6
EV / EBITDA 22.915.812.711.421.518.513.213.914.612.914.813.3
EV / FCF 18.918.632.536.934.632.521.222.726.019.219.818.6
EV / Revenue 2.42.32.92.75.24.22.83.03.32.83.32.8
Earnings Yield -1.4%0.11%3.9%4.3%2.1%2.9%3.3%4.1%2.3%4.2%3.9%4.1%

Período más reciente a la izquierda · valores nulos mostrados como ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

16
Métrica 2025-12-272024-12-282023-12-302022-12-312021-12-25
Ingresos $4.02B $4.05B $4.13B $3.98B $3.54B
Margen Operativo % 0.63% 5.6% 14.9% 16.4% 16.7%
Beneficio neto $-144M $22M $475M $486M $391M
EPS Diluido $-2.91 $0.20 $9.22 $9.48 $7.60

Propietarios institucionales (13F) 607 declarantes · $13.6B total · A fecha de 30 de septiembre de 2026

17

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Tenedores 607
Valor en tenencia $13.6B
Nuevas posiciones 74
Posiciones cerradas 62
Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
74 (-17 vs trimestre anterior) 62 (-19 vs trimestre anterior) 193 (0 vs trimestre anterior) 204 (+13 vs trimestre anterior) +2.8M

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
VANGUARD GROUP INC $1 174 373 670 5 887 175 8,65% Acciones
FMR LLC $961 533 236 4 239 752 7,09% Acciones
BlackRock, Inc. $861 475 349 3 798 560 6,35% Acciones
VANGUARD CAPITAL MANAGEMENT LLC $714 227 026 3 149 288 5,26% Acciones
Invesco Ltd. $676 919 391 2 984 785 4,99% Acciones
HARRIS ASSOCIATES L P $508 269 048 2 241 144 3,75% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $501 427 927 2 210 979 3,70% Acciones
Allspring Global Investments Holdings, LLC $436 473 035 1 905 247 3,22% Acciones
STATE STREET CORP $422 800 968 1 864 284 3,12% Acciones
DIMENSIONAL FUND ADVISORS LP $373 848 597 1 648 450 2,76% Acciones
ARIEL INVESTMENTS, LLC $341 587 697 1 506 185 2,52% Acciones
GEODE CAPITAL MANAGEMENT, LLC $295 598 099 1 305 738 2,18% Acciones
WELLINGTON MANAGEMENT GROUP LLP $292 210 525 1 288 463 2,15% Acciones
CITADEL ADVISORS LLC $270 696 771 1 193 601 1,99% Acciones
BANK OF AMERICA CORP /DE/ $265 930 779 1 172 586 1,96% Acciones
EARNEST PARTNERS LLC $254 007 295 1 120 011 1,87% Acciones
AMERIPRISE FINANCIAL INC $199 834 979 881 189 1,47% Acciones
NEUBERGER BERMAN GROUP LLC $195 633 630 862 704 1,44% Acciones
SEI INVESTMENTS CO $184 499 540 813 530 1,36% Acciones
MORGAN STANLEY $181 542 851 800 487 1,34% Acciones
Clearbridge Investments, LLC $177 185 527 781 276 1,31% Acciones
COOKE & BIELER LP $171 369 328 755 630 1,26% Acciones
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ $157 642 604 682 173 1,16% Acciones
VICTORY CAPITAL MANAGEMENT INC $150 762 735 664 768 1,11% Acciones
UBS Group AG $146 675 752 646 747 1,08% Acciones
GOLDMAN SACHS GROUP INC $145 100 822 639 803 1,07% Acciones
MILLENNIUM MANAGEMENT LLC $110 324 717 486 462 0,81% Acciones
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $106 061 291 467 663 0,78% Acciones
BANK OF MONTREAL /CAN/ $104 270 783 459 768 0,77% Acciones
NORTHERN TRUST CORP $101 169 205 446 092 0,75% Acciones
Gotham Asset Management, LLC $98 233 181 433 146 0,72% Acciones
Amundi $93 528 650 412 402 0,69% Acciones
NORGES BANK $83 921 372 370 040 0,62% Acciones
MARSHALL WACE, LLP $77 787 835 342 995 0,57% Acciones
Iron Triangle Partners LP $75 748 141 379 728 0,56% Acciones
CITIGROUP INC $71 714 853 316 217 0,53% Acciones
BNP PARIBAS FINANCIAL MARKETS $69 108 583 304 725 0,51% Acciones
Bank of New York Mellon Corp $69 054 385 304 486 0,51% Acciones
Boston Trust Walden Corp $65 523 486 288 917 0,48% Acciones
JPMORGAN CHASE & CO $65 085 033 286 317 0,48% Acciones
ALLIANCEBERNSTEIN L.P. $64 615 913 374 585 0,48% Acciones
SNYDER CAPITAL MANAGEMENT L P $63 899 443 281 756 0,47% Acciones
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $63 174 169 278 558 0,47% Acciones
DEUTSCHE BANK AG\ $62 723 084 276 569 0,46% Acciones
VANGUARD FIDUCIARY TRUST CO $61 384 115 270 665 0,45% Acciones
PRIMECAP MANAGEMENT CO/CA/ $60 523 448 266 870 0,45% Acciones
RAYMOND JAMES FINANCIAL INC $58 234 910 256 779 0,43% Acciones
Meridiem Capital Partners LP $56 012 367 246 979 0,41% Acciones
Alyeska Investment Group, L.P. $53 295 650 235 000 0,39% Acciones
LOOMIS SAYLES & CO L P $50 725 593 223 668 0,37% Acciones

Mostrar todos los 607 propietarios institucionales →

Activistas y propietarios del %+ 5 6 tenencias

18

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
JANA PARTNERS LLC ×4 presentaciones 4 de agosto de 2011 · Presentación inicial · SEC
Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 presentaciones 9 de febrero de 2011 · Presentación inicial · SEC
Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 presentaciones 7 de diciembre de 2010 · Presentación inicial · SEC
Persona informante no revelada 16 de junio de 2010 · Presentación inicial · SEC
Persona informante no revelada 7 de junio de 2010 · Presentación inicial Inversión pasiva SEC
Charles River Laboratories International, Inc. IRS No. 061397316 5 de mayo de 2010 · Presentación inicial Campaña de la junta directiva SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Informantes de la empresa 57 insiders · 23 directivos · 29 consejeros

19
Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
Birgit Girshick Chief Executive Officer 19 de agosto de 2026 G 35 485 0 1 $-1 819 350
Glenn Coleman EVP & Chief Financial Officer 30 de septiembre de 2026 P 27 762 1 0 $2 974
Flavia Pease Corporate Executive VP & CFO 31 de mayo de 2025 F 17 297 0 0 $0
David Ross Smith Corporate Executive VP & CFO 3 de marzo de 2022 M 25 819 0 0 $0
Davide Molho President & COO 24 de julio de 2018 M 17 155 0 0 $0
Shannon M Parisotto CEVP, Disc & Safety Assessment 19 de agosto de 2026 M 4 807 0 3 $-2 965 466
Mark Mintz EVP, Chief Information Officer 31 de mayo de 2026 F 9 546 0 0 $0
William D Barbo Corporate Executive VP & CCO 7 de noviembre de 2024 G 23 337 0 0 $0
John W Kuo CEVP General Counsel & CCO 1 de junio de 2020 A 3 171 0 0 $0
David P Johst Corporate Executive VP 29 de mayo de 2020 A 224 478 0 0 $0
John J Crowley SVP, Chief Accounting Officer 1 de octubre de 2016 F 5 599 0 0 $0
Nancy Gillett Corporate Executive VP 2 de marzo de 2016 S 11 034 0 0 $0
Jorg Geller Corporate Executive VP 25 de febrero de 2015 M 14 094 0 0 $0
RENAUD REAL H Corp. Executive VP 11 de agosto de 2010 F 74 390 0 0 $0
Christopher Berthoux Executive Vice President 26 de febrero de 2010 A 31 897 0 0 $0
Joanne P Acford Corp. Sr VP, GC and Corp. Sec 11 de agosto de 2007 F 37 109 0 0 $0
David J Elliott Officer 29 de junio de 2007 M 11 750 0 0 $0
Cheri L Walker Corporate Senior VP 1 de mayo de 2007 A 6 262 0 0 $0
Stephanie B Wells Senior Vice President 2 de abril de 2007 A 11 500 0 0 $0
Nicholas Ventresca Senior Vice President 2 de abril de 2007 F 12 713 0 0 $0
John C Ho Senior Vice President 23 de febrero de 2007 A 12 710 0 0 $0
Brian Bathgate Corporate Vice President 27 de febrero de 2006 S 16 134 0 0 $0
Alastair Stuart Mcewan Corporate VP 23 de diciembre de 2004 M 8 000 0 0 $0
James C Foster Consejero 25 de agosto de 2026 M 31 596 0 3 $-34 844 875
Nancy C Andrews Consejero 18 de agosto de 2026 M 1 438 0 1 $-163 443
Steven Barg Consejero 2 de junio de 2026 A 3 287 0 0 $0
Reshema Kemps-Polanco Consejero 8 de mayo de 2026 A 4 563 0 0 $0
George Llado Consejero 8 de mayo de 2026 A 6 702 0 0 $0
Abraham Ceesay Consejero 8 de mayo de 2026 A 2 384 0 0 $0
Mark J Enyedy Consejero 8 de mayo de 2026 A 2 384 0 0 $0
Paul W Graves Consejero 8 de mayo de 2026 A 2 384 0 0 $0
Craig B. Thompson Consejero 8 de mayo de 2026 A 3 851 0 0 $0
Martin Mackay Consejero 8 de mayo de 2026 A 17 137 0 0 $0
Virginia M Wilson Consejero 8 de mayo de 2026 A 6 349 0 0 $0
George Massaro Consejero 15 de mayo de 2025 S 5 575 0 0 $0
Richard F Wallman Consejero 7 de noviembre de 2024 S 0 0 0 $0
Deborah Turner Kochevar Consejero 13 de mayo de 2024 A 7 894 0 0 $0
Robert J Bertolini Consejero 13 de mayo de 2024 A 32 802 0 0 $0
Richard C Reese Consejero 15 de mayo de 2023 A 65 541 0 0 $0
George M Milne JR Consejero 7 de mayo de 2021 A 29 079 0 0 $0
Stephen D Chubb Consejero 23 de febrero de 2021 M 40 529 0 0 $0
Jean-Paul Mangeolle Consejero 22 de mayo de 2019 A 3 886 0 0 $0
William Waltrip Consejero 5 de diciembre de 2012 S 21 830 0 0 $0
Samuel O Thier MD Consejero 9 de mayo de 2012 A 18 230 0 0 $0
Douglas E Rogers Consejero 7 de mayo de 2010 A 12 859 0 0 $0
Nancy T Chang Consejero 7 de mayo de 2010 A 31 010 0 0 $0
Linda Mcgoldrick Consejero 13 de febrero de 2006 A · 0 0 $0
Walter S Nimmo Consejero 25 de febrero de 2005 S 149 447 0 0 $0
John Urquhart Consejero 17 de febrero de 2005 A 11 738 0 0 $0
Louise S Mccrary Consejero 17 de febrero de 2005 A · 0 0 $0
Robert Cawthorn Consejero 2 de junio de 2004 G 278 600 0 0 $0
Joseph W Laplume · 10 de agosto de 2026 G 31 041 1 1 $-61 124
Victoria L Creamer · 6 de agosto de 2026 M 30 051 0 1 $-1 083 030
Michael Gunnar Knell · 6 de agosto de 2026 M 11 852 0 9 $-1 730 250
Thomas F Ackerman · 29 de febrero de 2016 F 111 346 0 0 $0
Dennis R Shaughnessy · 29 de noviembre de 2004 G 35 511 0 0 $0
Michael F Ankcorn · 4 de noviembre de 2004 S 0 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Propiedad de ETFs Mantenido por 106 ETFs

20

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
EPSB · Harbor ETF Trust 2,15% 443 NS 31 de julio de 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,73% 51 248 SH 1 de octubre de 2026 Diario
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1,71% 5 092 NS 31 de julio de 2026 N-PORT
EPSV · Harbor ETF Trust 1,59% 415 NS 31 de julio de 2026 N-PORT
EPMV · Harbor ETF Trust 1,44% 291 NS 31 de julio de 2026 N-PORT
ALTL · Pacer Funds Trust 1,09% 4 303 NS 31 de julio de 2026 N-PORT
IBB · iShares Trust 0,96% 363 741 SH 11 de septiembre de 2026 Diario
LSEQ · Harbor ETF Trust 0,93% 614 NS 31 de julio de 2026 N-PORT
HIBL · Direxion Shares ETF Trust 0,74% 2 375 NS 31 de julio de 2026 N-PORT
SPHB · Invesco Exchange-Traded Fund Trust … 0,69% 22 191 SH 1 de octubre de 2026 Diario
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,66% 259 NS 31 de julio de 2026 N-PORT
PALC · Pacer Funds Trust 0,61% 5 509 NS 31 de julio de 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0,49% 12 141 NS 31 de julio de 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,45% 6 439 NS 31 de julio de 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0,44% 24 918 SH 1 de octubre de 2026 Diario
FFSM · FIDELITY COVINGTON TRUST 0,40% 25 814 NS 31 de julio de 2026 N-PORT
DFAT · Dimensional ETF Trust 0,34% 209 615 NS 31 de julio de 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,28% 7 783 NS 31 de julio de 2026 N-PORT
ESML · iShares Trust 0,24% 25 082 SH 11 de septiembre de 2026 Diario
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,24% 20 898 NS 31 de julio de 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,24% 25 378 NS 31 de julio de 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0,23% 13 626 NS 31 de julio de 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0,23% 701 498 SH 19 de agosto de 2026 Diario
DFAS · Dimensional ETF Trust 0,22% 147 648 NS 31 de julio de 2026 N-PORT
RSP · Invesco Exchange-Traded Fund Trust 0,22% 702 813 SH 1 de octubre de 2026 Diario
IYH · iShares Trust 0,22% 28 670 SH 11 de septiembre de 2026 Diario
SMMD · iShares Trust 0,19% 26 152 SH 11 de septiembre de 2026 Diario
IXJ · iShares Trust 0,17% 25 598 SH 11 de septiembre de 2026 Diario
FHLC · FIDELITY COVINGTON TRUST 0,17% 23 486 NS 31 de julio de 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,16% 148 331 SH 19 de agosto de 2026 Diario
REVS · Columbia ETF Trust I 0,15% 2 111 NS 31 de julio de 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0,15% 3 646 NS 31 de julio de 2026 N-PORT
WSML · iShares Trust 0,14% 6 080 SH 11 de septiembre de 2026 Diario
IWS · iShares Trust 0,13% 73 404 SH 11 de septiembre de 2026 Diario
VB · VANGUARD INDEX FUNDS 0,13% 1 102 914 SH 19 de agosto de 2026 Diario
CURE · Direxion Shares ETF Trust 0,13% 947 NS 31 de julio de 2026 N-PORT
DFSV · Dimensional ETF Trust 0,12% 42 976 NS 31 de julio de 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,10% 2 764 SH 1 de octubre de 2026 Diario
IEUS · iShares Trust 0,10% 5 579 SH 11 de septiembre de 2026 Diario
IWR · iShares Trust 0,10% 200 615 SH 11 de septiembre de 2026 Diario
RECS · Columbia ETF Trust I 0,10% 23 999 NS 31 de julio de 2026 N-PORT
XOEF · iShares Trust 0,07% 61 SH 11 de septiembre de 2026 Diario
DFUV · Dimensional ETF Trust 0,06% 41 352 NS 31 de julio de 2026 N-PORT
DXUV · Dimensional ETF Trust 0,06% 1 302 NS 31 de julio de 2026 N-PORT
DFAC · Dimensional ETF Trust 0,05% 106 991 NS 31 de julio de 2026 N-PORT
IVE · iShares Trust 0,04% 79 930 SH 11 de septiembre de 2026 Diario
IUSV · iShares Trust 0,04% 42 675 SH 11 de septiembre de 2026 Diario
SCZ · iShares Trust 0,04% 171 786 SH 11 de septiembre de 2026 Diario
VSS · VANGUARD INTERNATIONAL EQUITY INDEX… 0,04% 174 824 SH 19 de agosto de 2026 Diario
VOOV · VANGUARD ADMIRAL FUNDS 0,04% 11 139 SH 19 de agosto de 2026 Diario
DCOR · Dimensional ETF Trust 0,04% 5 545 NS 31 de julio de 2026 N-PORT
IWD · iShares Trust 0,04% 108 791 SH 11 de septiembre de 2026 Diario
CHRI · Global X Funds 0,03% 11 NS 31 de julio de 2026 N-PORT
VONV · VANGUARD SCOTTSDALE FUNDS 0,03% 29 579 SH 19 de agosto de 2026 Diario
PRF · Invesco Exchange-Traded Fund Trust 0,03% 9 073 SH 1 de octubre de 2026 Diario
TOPC · iShares Trust 0,03% 32 SH 11 de septiembre de 2026 Diario
DFSU · Dimensional ETF Trust 0,02% 2 431 NS 31 de julio de 2026 N-PORT
XVV · iShares Trust 0,02% 576 SH 11 de septiembre de 2026 Diario
QVML · Invesco Exchange-Traded Fund Trust … 0,02% 1 252 SH 1 de octubre de 2026 Diario
PBP · Invesco Exchange-Traded Fund Trust 0,02% 287 SH 30 de septiembre de 2026 Diario
RWL · Invesco Exchange-Traded Fund Trust … 0,02% 7 028 SH 1 de octubre de 2026 Diario
EGLE · Global X Funds 0,02% 2 NS 31 de julio de 2026 N-PORT
IVV · iShares Trust 0,02% 607 129 SH 11 de septiembre de 2026 Diario
VOO · VANGUARD INDEX FUNDS 0,02% 1 250 774 SH 19 de agosto de 2026 Diario
VTI · VANGUARD INDEX FUNDS 0,02% 1 530 468 SH 19 de agosto de 2026 Diario
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 8 168 SH 19 de agosto de 2026 Diario
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 4 112 SH 19 de agosto de 2026 Diario
ESGV · VANGUARD WORLD FUND 0,02% 11 106 SH 19 de agosto de 2026 Diario
IWV · iShares Trust 0,02% 14 165 SH 11 de septiembre de 2026 Diario
IWB · iShares Trust 0,02% 33 863 SH 11 de septiembre de 2026 Diario
XRMI · Global X Funds 0,02% 41 NS 31 de julio de 2026 N-PORT
DFAU · Dimensional ETF Trust 0,02% 9 979 NS 31 de julio de 2026 N-PORT
XYLD · Global X Funds 0,02% 2 566 NS 31 de julio de 2026 N-PORT
IYY · iShares Trust 0,02% 2 018 SH 11 de septiembre de 2026 Diario
ITOT · iShares Trust 0,02% 63 582 SH 11 de septiembre de 2026 Diario
PHDG · Invesco Actively Managed Exchange-T… 0,02% 38 SH 1 de octubre de 2026 Diario
PTLC · Pacer Funds Trust 0,02% 2 492 NS 31 de julio de 2026 N-PORT
TILT · FlexShares Trust 0,02% 1 620 NS 31 de julio de 2026 N-PORT
DFUS · Dimensional ETF Trust 0,02% 14 645 NS 31 de julio de 2026 N-PORT
XYLG · Global X Funds 0,02% 45 NS 31 de julio de 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0,02% 182 NS 31 de julio de 2026 N-PORT
QDPL · Pacer Funds Trust 0,02% 1 141 NS 31 de julio de 2026 N-PORT
XTR · Global X Funds 0,01% 3 NS 31 de julio de 2026 N-PORT
HCMT · Direxion Shares ETF Trust 0,01% 332 NS 31 de julio de 2026 N-PORT
SPXL · Direxion Shares ETF Trust 0,01% 3 766 NS 31 de julio de 2026 N-PORT
IEUR · iShares Trust 0,01% 37 473 SH 11 de septiembre de 2026 Diario
XCLR · Global X Funds 0,01% 2 NS 31 de julio de 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,01% 1 973 SH 1 de octubre de 2026 Diario
VGK · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 110 946 SH 19 de agosto de 2026 Diario
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 77 796 SH 19 de agosto de 2026 Diario
VEA · VANGUARD TAX-MANAGED FUNDS 0,01% 447 656 SH 19 de agosto de 2026 Diario
IDEV · iShares Trust 0,01% 52 174 SH 11 de septiembre de 2026 Diario
IEFA · iShares Trust 0,00% 272 340 SH 11 de septiembre de 2026 Diario
NEAR · iShares U.S. ETF Trust 0,00% 140 000 SH 9 de septiembre de 2026 Diario
DFLV · Dimensional ETF Trust 0,00% 377 NS 31 de julio de 2026 N-PORT
IXUS · iShares Trust 0,00% 22 623 SH 11 de septiembre de 2026 Diario
VXUS · VANGUARD STAR FUNDS 0,00% 664 961 SH 19 de agosto de 2026 Diario
VSGX · VANGUARD WORLD FUND 0,00% 8 805 SH 19 de agosto de 2026 Diario
VGHY · VANGUARD FIXED INCOME SECURITIES FU… · · 15 de julio de 2026 Diario
VCRB · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VPLS · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VSDB · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VGMS · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
ISCB · iShares Trust · 2 146 SH 11 de septiembre de 2026 Diario
ISCV · iShares Trust · 10 576 SH 11 de septiembre de 2026 Diario
SMLF · iShares Trust · 18 703 SH 11 de septiembre de 2026 Diario

CRL Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

21
calificación · 23 analistas COMPRA
Objetivo mediano $322.00 +11,0%
6 26,1% Compra fuerte
11 47,8% Compra
6 26,1% Mantener
0 0,0% Venta
0 0,0% Venta fuerte

Precio objetivo a 12 meses

15 analistas · 2026-10-02

Objetivo medio $305.00 +5,1%

Ahora Precio Actual $290.19
Mín$145.00 Media$305.00 Máx$357.00

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

22

Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
CRL $10.02B -70.0 -0.85% -3.6% -4.4% ·
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9% ·
RVTY $10.86B 46.7 3.7% 8.5% 3.3% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TXG $2.08B -46.6 5.2% -6.8% -5.5% 69.0%
TECH $11.03B 60.9 -0.38% 15.0% 9.0% 65.8%
RGEN $9.23B 190.5 16.4% 6.6% 2.4% ·
AVTR $7.82B -14.7 -3.4% -8.1% -8.9% 32.6%
BIO · · · · · ·

Últimas noticias Noticias recientes que mencionan a esta empresa

23
Bio-Techne toma el puesto #477 de Charles River Laboratories International Nasdaq · 3 meses atrás Charles River Laboratories International Llamada de ganancias del primer trimestre Puntos destacados Yahoo Finance · 4 meses, 3 semanas atrás Títulos del Tesoro de EE. UU. tokenizados se acercan a los 14 mil millones de dólares a medida que Circle y BlackRock lideran el crecimiento Yahoo Finance · 5 meses, 2 semanas atrás

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

26

Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Fuente: SEC 10-Q presentada el Ago 5, 2026